Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review

The literature review discusses approaches to the treatment of patients with chronic heart failure and preserved ejection fraction (EF>50) – HFpEF. The impact of various groups of drugs on the prognosis and quality of life of patients in this cohort was assessed based on the results of randomized trials, systematic reviews and meta-analyses, clinical recommendations of recent years. To date, only sodium-glucose cotransporter-2 inhibitors unequivocally improve the quality of life and prognosis of patients with HFpEF. Angiotensin receptor – neprilysin inhibitors and mineralocorticoid receptor antagonists are effective in terms of prognosis and quality of life only in patients with HFpEF in combination with resistant hypertension. In patients with sinus rhythm, heart rate > 70 beats/min and concomitant coronary artery disease, a combination of bisoprolol and ivabradine may be considered. Diuretics are recommended for patients with HFpEF when there are signs of congestion and signs of decompensation. Other groups of drugs do not significantly affect the quality of life and prognosis of patients with HFpEF and can be prescribed to such patients only as part of planned therapy for the treatment of other concomitant cardiovascular diseases.

1. Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016; 8: 7–13 (In Russian). https://doi.org/10.15829/1560-4071-2016-8-7-13. EDN: WHURET

2. Anker S.D., Butler J., Filippatos G., et al. EMPEROR-Preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385(16): 1451–1461. https://doi.org/10.1056/NEJMoa2107038. PMID: 34449189

3. Nassif M.E., Windsor S.L., Borlaug B.A., et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021; 27(11): 1954–1960. https://doi.org/10.1038/s41591-021-01536-x. PMID: 34711976

4. Pandey A.K., Dhingra N.K., Hibino M., et al. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis. ESC Heart Fail 2022; 9(2): 942–946. https://doi.org/10.1002/ehf2.13805. PMID: 35112512

5. Heidenreich P.A., Bozkurt B., Aguilar D., et al. 2022 AHA/ACC/ HFSA Guideline for the management of heart failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 2022; 3; 145(18): e895–e1032. https://doi.org/10.1161/CIR.0000000000001063. PMID: 35363499.

6. Wintrich J., Abdin A., Böhm M. Management strategies in heart failure with preserved ejection fraction. Herz. 2022; 6: 1–8. https://doi.org/10.1007/s00059-022-05119-5. PMID: 35524007

7. Fu M., Zhou J., Sun A., et al. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction – A meta analysis of 7 prospective clinical studies. Int J Cardiol. 2012 Feb 23; 155(1): 33–38. https://doi.org/10.1016/j.ijcard.2011.01.081. Epub 2011 Apr 11. PMID: 21481482.

8. Martin N., Manoharan K., Davies C., Lumbers R.T. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev 2021 May 22; 5(5): CD012721. https://doi.org/10.1002/14651858.CD012721.pub3. PMID: 34022072

9. McDonagh T.A., Metra M., Adamo M., et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726. https://doi.org/10.1093/eurheartj/ehab368. PMID: 34447992. Corrigendum: Eur Heart J. 2021; 42(48): 4901. https://doi.org/10.1093/eurheartj/ehab670

10. Pieske B., Wachter R., Shah S.J., et al. PARALLAX Investigators and Committee members. Effect of Sacubitril/Valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: The PARALLAX randomized clinical trial. JAMA. 2021; 326(19): 1919–1929. https://doi.org/10.1001/jama.2021.18463. PMID: 34783839

11. Jackson A.M., Jhund P.S., Anand I.S., et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021 Sep 21; 42(36): 3741–3752. https://doi.org/10.1093/eurheartj/ehab499. PMID: 34392331

12. Komajda M., Isnard R., Cohen-Solal A., et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial: Ivabradine in HFpEF. European Journal of Heart Failure 2017; 19 (11): 1495–1503. https://doi.org/10.1002/ejhf.876. PMID: 28462519.

13. Babushkina G.V., Shaikhlislamova G.I. Ivabradine for treatment of heart failure with preserved ejection fraction. Kardiologiya. 2020; 10; 60(10): 33–37 (In Russian). https://doi.org/10.18087/cardio.2020.10.n1324. EDN: BPDUAN

14. Tsujimoto T., Kajio H. Spironolactone use and improved outcomes in patients with heart failure with preserved ejection fraction with resistant hypertension. J Am Heart Assoc. 2020; 9(23): e018827. https://doi.org/10.1161/JAHA.120.018827. PMID: 33222584

15. Lund L.H., Claggett B., Liu J., et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018; 20(8): 1230–1239. https://doi.org/10.1002/ejhf.1149. PMID: 29431256

16. Rao V.N., Pandey A., Zhong L., et al. Loop Diuretic Use and Outcomes in Chronic Stable Heart Failure With Preserved Ejection Fraction-Reply. Mayo Clin Proc. 2021 Feb; 96(2):503–506. https://doi.org/10.1016/j.mayocp.2020.11.006. PMID: 33549271.

17. Hashim T., Elbaz S., Patel K., et al. Digoxin and 30-day all-cause hospital admission in older patients with chronic diastolic heart failure. Am J Med. 2014; 127(2): 132–139. https://doi.org/10.1016/j.amjmed.2013.08.006. PMID: 24067296

18. Hashemi-Shahri S.H., Aghajanloo A., Ghavami V., et al. Digoxin and outcomes in patients with heart failure and preserved ejection fraction [HFpEF] patients: A systematic review and meta-analysis. Curr Drug Targets. 2022 Sep 6. Epub ahead of print. https://doi.org/10.2174/1389450123666220906093058. PMID: 36065922.

19. Redfield M.M., Anstrom K.J., Levine J.A., et al. NHLBI heart failure clinical research network. Isosorbide Mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015; 373(24): 2314–2324. https://doi.org/10.1056/NEJMoa1510774. PMID: 26549714

20. Wang X., Ju J., Chen Z., et al. Associations between calcium channel blocker therapy and mortality in heart failure with preserved ejection fraction. Eur J Prev Cardiol. 2022 Jul 20; 29(9): 1343–1351. https://doi.org/10.1093/eurjpc/zwac004. PMID: 35015840.